Fidaxomicin (Dificlir®) 200 mg film-coated tablets
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000038
English
Authors' recommendations:
Fidaxomicin (Dificlir®) is recommended as an option for restricted use within NHS Wales.
Fidaxomicin (Dificlir®) should be restricted for use in the following subpopulations within its licensed indication for the treatment of adults with Clostridium difficile infections (CDI), also known as C. difficileassociated diarrhoea (CDAD):
- Patients with severe CDI
- Patients with recurrence of CDI
Fidaxomicin (Dificlir®) should be prescribed on the advice of a consultant microbiologist, consistent with Health Protection Agency guidance. Fidaxomicin (Dificlir®) is not recommended for use within NHS Wales outside the specified subpopulations.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/fidaxomicin%20%28Dificlir%29%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Clostridium Infections
- Clostridioides difficile
- Fidaxomicin
- Anti-Bacterial Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.